T cell receptor (TCR) engineering cell therapy is a form of T cell engineering using T cells obtained from a patient. Once harvested, T cells are modified in a laboratory setting. T cells are engineered to express a TCR that recognizes major histocompatibility complex (MHC) proteins on tumor cells. Engagement of a TCR and MHC molecule initiates the anti-tumor immune response.
-
JUL 26, 2023 | 11:20 AM
C.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
Date: May 31, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Introducing Nanostring’s latest spatial platform, CosMx Spatial Molecular Imager (SMI). Offering high-plex, multiomi...
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
Genome editing technologies have enabled the precise manipulation of DNA sequences at targeted sites to achieve therapeutic effects. Engineered endonucleases like CRISPR-Cas9 institute site-...
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
DATE: June 23, 2020 TIME: 6:00 am PDT, 9:00 am EDT In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies t...